Neurodegenerative disease

…in aging, menopause and age-related neurodegenerative disease, primarily using neuroimaging and non-invasive brain stimulation. The associate will develop new neuroimaging tasks from existing laboratory work, collect longitudinal behavioural, neuroimaging and brain-stimulation data from community-based participants, analyse large neuroimaging and time-series datasets, lead papers with a focus on longitudinal analysis of cerebellar measures, contribute to progress

Lead experimental studies that identify and validate targets for neurodegenerative disease. Design rodent experiments, analyse human and animal brain tissue, and develop quantitative measures of protein aggregation, inflammation, cell loss and vascular integrity. Collaborate with pharmacology, histology, molecular biology and computational teams to turn mechanistic findings into programme decisions. The employer’s current vacancy accepts applications without a stated fixed deadline.

Ataxia-telangiectasia (A-T) is a devastating and rare autosomal recessive neurodegenerative disease. It is characterised by progressive neurological pathology, among other symptoms, and caused by mutations in the ataxia-telangiectasia mutated (ATM) gene. The molecular mechanisms underlying the disease are poorly understood, partly due to a lack of appropriate animal and cellular models. Here, we use human tissue and Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to produce deep RNA-sequencing expression profiles (>12000 genes) of purified CNS cell typ

Therapies for neurodegenerative disease are limited in efficacy and tolerability, largely due to poor drug penetration across the BBB and off-target effects. Polymeric nanoparticles (NPs) are advantageous for brain drug delivery due to their safety profiles, drug-loading capacity, controlled-release properties and potential for drug repurposing. The aim of this work was to perform in vitro screening of NPs synthesised using the FDA-approved poly(lactic co-glycolic acid) (PLGA) polymer as drug delivery vehicles in primary rat neurons and glia as a prerequisite for further assessment in animal m

…death in cognitive drug discovery for neurodegenerative disease. Synapse strengthening may prevent or reverse neurodegeneration. However, screening for compounds that achieve this requires a network capable of synapse strengthening and weakening that is supported by human astrocytes and microglia, i.e. a fully human model system of a minimal brain circuit.So far, convincing post-synaptic immunostains of hIPSC-derived neurons are rare, as

…treatment of patients with Alzheimer's disease. Alzheimer is the most current form of dementia, affecting millions of patients worldwide. As a neurodegenerative disease, it is associated with a progressive degradation process in the brain, leading to cognitive and functional impairment. Various forms of standard therapies are currently used to slow down the progression of the disease. However, their effective benefits and possible side effects should always be weighted up prior prescription. TPS is a relatively new drug-f